Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2025

Genmab — April 2025

Planlagt Fastgjort Låst Flyttet Genmab
294 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Stroka
    wrote on sidst redigeret af
    #197

    God morgen 🙂

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #198

      small new trial by The Lymphoma Academic Research Organisation - Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (E-REVRI) https://clinicaltrials.gov/study/NCT06931652

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #199

        central nervous system (CNS)

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #200

          EPCORE™ CLL-1 adds 120 patients , for Treatment-naïve (TN) and high risk (HR) CLL https://clinicaltrials.gov/study/NCT04623541?tab=history&a=26&b=27&compareMode=sideBySide#version-content-panel

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #201

            Thx EL I can only read that as very bullish.

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #202

              I forbindelsemed Abbvie's sag mod Genmab / Profound Bio, vil jeg høre om der er interesse for at indsamle ca. 305 USD til Proinvester så Helge og medarbed kan downloade Abbvie's indsendte beviser De ligger uploaded på PACER og kan downloades mod betaling af 0,10 USD or side. Beviserne dækker 3003 sider.

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #203

                Er der nogen der har adgang til ØUs artikel fra 18/4. https://ugebrev.dk/formue/genmab-laserskarpt-fokus-trods-tilbageslag/

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #204

                  the Rinatabart Sesutecan Ph1/2 adds an endometrial cancer cohort, 100+ extra patients https://clinicaltrials.gov/study/NCT05579366?tab=history&a=23&b=24&compareMode=sideBySide#version-content-panel

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #205

                    as a reminder, we will get data on endometrial cancer in the first half of this year at a major cancer conference

                    1 Reply Last reply
                    0
                    • A Offline
                      A Offline
                      Anders_
                      wrote on sidst redigeret af
                      #206

                      E L 15:35 Do you know what date the conference is?

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #207

                        no, not yet Anders

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          JKY_VH
                          wrote on sidst redigeret af
                          #208

                          Fra MW "Genmab har fået løftet kursmålet for sin amerikanske notering til 29 dollar fra 27 dollar hos den amerikanske investeringsbank Leerink Partners.

                          Det viser data fra Bloomberg News.

                          Anbefalingen er stadig "outperform".

                          Der går ti af Genmabs ADR-aktier på én dansk. Det nye kursmål svarer således til 1877,90 kr."

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #209

                            Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1306225/transactions-in-connection-with-share-buy-back-program

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #210

                              Amerikansk politik presser biotekaktierne https://proinvestor.com/investornyt/1306176/amerikansk-politik-presser-biotekaktierne

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #211

                                https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2025_en.pdf Teprotumumab
                                on EMA CHMP agenda

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #212

                                  more for the academics i guess, as it has been terminated - DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma https://elifesciences.org/reviewed-preprints/106425#x1684353369

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #213

                                    ASCO titles released.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #214

                                      ASCO25 Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.

                                      Abstract: 3039

                                      | Poster Bd #: 354

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #215

                                        ASCO25 A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).

                                        Abstract: TPS5627

                                        | Poster Bd #: 520b

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #216

                                          ASCO25 New Drugs in Oncology: Incorporation Into Practice - Presentation 2 -

                                          Epcoritamab for Relapsed or Refractory Follicular Lymphoma

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper